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Abstract
Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl 
tamoxifen (endoxifen), both with greater anti-estrogenic potency than the parent drug. Patients 
with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors 
exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of 
tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and 
provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.
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The purpose of this guideline is to provide clinicians information that will allow the 
interpretation of clinical CYP2D6 genotype tests so that the results can be used to guide 
prescribing of tamoxifen. Detailed guidelines for use of tamoxifen as well as analyses of 
cost effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics 
Implementation Consortium (CPIC) guidelines are periodically updated at 
www.cpicpgx.org/guidelines/.
FOCUSED LITERATURE REVIEW
A systematic literature review focused on CYP2D6 genotype and tamoxifen use (details in 
Supplement) was conducted.
GENE: CYP2D6
CYP2D6 is highly polymorphic with over 100 known allelic variants and subvariants 
identified (https://www.pharmvar.org/gene/CYP2D6); CYP2D6 Allele Definition Table 
(1)). CYP2D6 alleles have been extensively studied in multiple geographically, racially, and 
ethnically diverse groups and significant differences in allele frequencies have been 
observed (CYP2D6 Frequency Table (1)). The most commonly reported alleles are 
categorized into functional groups as follows: Normal function (e.g., CYP2D6*1 and *2), 
decreased function (e.g., CYP2D6*9, *10, *17, and *41), and no function (e.g., CYP2D6*3, 
*4, *5, *6) (2, 3). Because CYP2D6 is subject to gene deletions, duplications or 
multiplications, many clinical laboratories also report copy number variations. CYP2D6*5 
represents a gene deletion (no function allele) whereas gene duplications and multiplications 
are denoted by “xN” (e.g. CYP2D6*1xN with xN representing the number of CYP2D6 gene 
copies). Alleles carrying two or more normal function gene copies are categorized as alleles 
with increased function.
The combination of alleles is used to determine a patient’s diplotype (Table 1). Each 
functional status is assigned an activity value ranging from 0 to 1 (e.g. 0 for no function, 0.5 
for decreased and 1.0 for normal function) (3). Table S1 describes the activity score values 
assigned to selected alleles. If an allele contains multiple copies of a functional gene, the 
value is multiplied by the number of copies present. Thus, the CYP2D6 activity score that is 
used to define CYP2D6 phenotype is the sum of the values assigned to each allele, which 
typically ranges from 0 to 3.0 but may exceed 3.0 in rare cases (3). See the CYP2D6 
Diplotype-Phenotype Table (1) for a complete list of possible diplotypes and phenotype 
assignment.
The CYP2D6 activity score has been translated into the phenotype classification system for 
other CPIC guidelines (4, 5) as follows (CYP2D6 Allele Definition Table (1)): patients with 
an activity score (AS) of 0 are poor metabolizers (PMs), those with a score of 0.5 are 
considered intermediate metabolizers (IMs), and those with a score of 1.5 or 2.0 represent 
normal metabolizers (NMs). Patients with a score >2.0 are classified as ultrarapid 
metabolizers (UMs). However, the activity score of 1.0 has less activity towards tamoxifen 
compared to those with an AS of 1. 5 or 2.0 and patients with an activity score of 1.0 may be 
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classified as IMs by some reference laboratories. Thus, for this guideline, an activity score of 
1.0 is classified as a CYP2D6 normal metabolizer or intermediate metabolizer, (Table 1). 
This is in contrast to the classification used in previous guidelines (4, 5). A group of 
CYP2D6 experts are currently working to standardize the CYP2D6 genotype to phenotype 
translation system. Note that genotypes with an activity score of 1 are classified as NMs in 
the CYP2D6 Genotype to Phenotype Table (1) and CPIC will update the CPIC website and 
this table accordingly when the CYP2D6 genotype to phenotype standardization is complete 
(6). Because reference laboratories providing clinical CYP2D6 genotyping may use varying 
methods to assign phenotypes, it is advisable to note a patient’s CYP2D6 diplotype and to 
calculate an activity score before making therapeutic decisions about tamoxifen therapy.
Genetic Test Interpretation
Clinical laboratories rarely sequence the entire CYP2D6 gene or interrogate every known 
variant position. Instead, they typically test for variants that are used to determine high 
frequency allele haplotypes using the star-allele (*) nomenclature system, found at the 
Pharmacogene Variation Consortium website (http://www.PharmVar.org). Table S1 and 
tables found on the CPIC and PharmGKB website contain a list of CYP2D6 alleles, the 
specific combination of variants that can be used to determine the allele, functional status, 
and frequency across major ethnic populations as reported in the literature (1, 6).
The limitations of genetic testing as described here include: (1) rare variants may not be 
detected; (2) known star (*) alleles not tested for will not be reported, and instead, the allele 
will be reported as a *1 and *3 tests are not designed to detect unknown or de novo variants. 
The Supplemental Material (Genetic Test Interpretation Section) contains additional 
information regarding CYP2D6 genetic test interpretation and phenotype assignment.
Available Genetic Test Options
See Supplemental Material and www.ncbi.nlm.nih.gov/gtr/ for more information on 
commercially available clinical testing options.
Incidental findings
Currently, there are no diseases or conditions that have been consistently linked to variation 
in the CYP2D6 gene independently of drug metabolism and response.
Other considerations
Chromosomal instability, i.e. loss of heterozygosity, is frequently observed in breast tumor 
tissue (7, 8). Genotype information derived from such tissue may therefore not accurately 
reflect the germline genotype that determines CYP2D6 activity in the liver where tamoxifen 
is metabolized. We therefore strongly recommend genotype testing be performed on non-
tumor DNA isolated from a peripheral blood, or a saliva/buccal swab sample.
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About 65–75% of breast cancer expresses estrogen receptors (ER) or progesterone receptors 
(PR) (9). In this group of patients, endocrine therapy represents the most important treatment 
modality. Tamoxifen, a selective estrogen receptor modulator (SERM), has been studied and 
utilized in breast cancer for more than 40 years. When administered to women with ER-
positive breast cancer for five years after surgery, tamoxifen almost halves the annual 
recurrence rate and reduces the breast cancer mortality rate by one-third in both pre- and 
post-menopausal women (10). While tamoxifen has multiple Food and Drug Administration 
(FDA) approvals for both the prevention and treatment of premenopausal and 
postmenopausal breast cancer, tamoxifen's continued importance is reflected by its status as 
the only hormonal agent approved by the FDA for the prevention of premenopausal breast 
cancer, the treatment of ductal carcinoma in situ, and the adjuvant and metastatic treatment 
of premenopausal invasive breast cancer.
The pharmacology of tamoxifen is complex. Tamoxifen is a weak anti-estrogen that is 
extensively metabolized, and its metabolites exhibit similar, less, or more potent anti-
estrogenic activity (11, 12). Furthermore, tamoxifen can exhibit either antiestrogenic or pro-
estrogenic properties, depending on the target tissue and the presence or absence of co-
activators or co-repressors (13, 14).
Tamoxifen undergoes extensive primary and secondary liver metabolism by cytochrome 
P450 enzymes via two major pathways: N-demethylation and 4-hydroxylation (Figure 1). 
The predominant metabolic pathway (considered to contribute to over 90% of tamoxifen 
metabolism) is the demethylation of tamoxifen to N-desmethyltamoxifen primarily mediated 
by CYP3A4 (15), followed by CYP2D6-mediated oxidation to 4-hydroxy-N-
desmethyltamoxifen (endoxifen) (16). A minor metabolic pathway is hydroxylation of 
tamoxifen (mediated mainly by CYP2D6 but also catalyzed by CYP3A4 and CYP2C19) to 
4-hydroxytamoxifen (4HT), which can then be further metabolized to endoxifen (17, 18). 
While tamoxifen and its metabolites undergo glucuronidation and sulfation, no consistent 
effect of pharmacogenetic variation in any of the UGT or SULT isoforms on either 
tamoxifen pharmacokinetics or clinical outcomes has been observed to date.
The hydroxylation of either tamoxifen or N-desmtheyltamoxifen is considered to bioactivate 
tamoxifen. Both 4HT and endoxifen exhibit nearly 100-fold greater anti-estrogenic potency 
than the parent drug (11, 19–24). Maximum inhibition of estrogen-induced stimulation and 
ER transcription is achieved with endoxifen concentrations of ranging between 100–1000 
nM (11). However, even low Z-endoxifen levels were necessary to block estrogen-mediated 
cell growth in models mimicking estrogen concentrations of pre- or postmenopausal women 
that were treated with tamoxifen and its metabolites (25, 26).
Both inter- and intra-individual variation in the concentration of tamoxifen and its 
metabolites have been described (16, 22, 27–29). As it relates to the active metabolites, 4HT 
concentrations are low, typically <5 nM (17, 22) and the role of interpatient variability in 
4HT as it relates to breast cancer outcomes is not well understood. In contrast, endoxifen 
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plasma concentrations are up to 10 fold higher than 4HT, exhibiting substantial variability 
(17, 22, 30). Patients with low CYP2D6 enzyme activity, as a result of CYP2D6 genetic 
polymorphisms or the co-administration of strong CYP2D6 inhibitors, exhibit significantly 
lower endoxifen concentrations when treated with tamoxifen (22, 31).
Clinical studies to evaluate the association between endoxifen concentrations and CYP2D6 
polymorphisms with tamoxifen outcome have yielded conflicting results. Initial (32) and 
follow-up data (33, 34) demonstrated that CYP2D6 PMs had an approximately two- to 
three-fold higher risk of breast cancer recurrence (compared to CYP2D6 NMs) and led an 
FDA special emphasis panel to recommend a tamoxifen label change to incorporate data that 
CYP2D6 genotype was an important biomarker associated with tamoxifen efficacy (35). 
However, this label change was not implemented because of conflicting data from secondary 
analyses of 5 year tamoxifen prospective trials including ATAC (36), BIG1-98 (37), and 
ABCSG 8 (38). Multiple other studies were summarized in a meta-analysis that 
demonstrated an association between CYP2D6 genotype and disease-free survival but only 
in patients that received tamoxifen as adjuvant therapy at a dose of 20 mg/day for five years 
(39).
Regarding the role of measurement of endoxifen concentrations, Madlensky et al identified 
an association between low endoxifen (lowest quintile) and recurrence (40). In a separate 
study of premenopausal patients, Saldores et al demonstrated similar findings that patients 
with low endoxifen concentrations (<14 nM) exhibited a higher risk for distant relapse or 
death compared with those with high concentrations (>35 nM) (41).
Given these conflicting data, a working group within CPIC was convened to review and 
summarize the strength of the data and to provide therapeutic recommendations for those 
patients in which CYP2D6 genotype is known and for whom adjuvant tamoxifen is 
recommended.
Linking genetic variability to variability in drug-related phenotypes
Endoxifen concentrations—There is substantial evidence linking CYP2D6 genotype 
with phenotypic variability in endoxifen concentrations. As outlined in Table S2, the 
evidence was considered uniformly strong that CYP2D6 PMs (AS=0) have lower plasma 
endoxifen concentrations among patients taking adjuvant tamoxifen compared to CYP2D6 
NMs, and that reduced CYP2D6 activity (AS=0 to 1) is associated with lower plasma 
endoxifen concentrations among patients taking adjuvant tamoxifen compared to normal 
CYP2D6 activity. CYP2D6 genotype explains 34–52% of the variability in absolute 
endoxifen concentrations (31). Of particular note, for populations with a high frequency of 
the decreased function CYP2D6*10 allele, there was strong evidence that patients with 
CYP2D6 activity scores of 0 to 1 had significantly lower plasma endoxifen concentrations 
compared to those with normal CYP2D6 activity (AS=1.5 and 2).
Pharmacodynamic markers (Ki–67)—One prospective clinical study examined the 
association between CYP2D6 genotype and change in tumor Ki-67, a phenotype linked to 
drug efficacy, in patients with early stage breast cancer receiving neoadjuvant tamoxifen. In 
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this study, patients with CYP2D6*10/*10 and CYP2D6*5/*10 genotypes had significantly 
lower Ki-67 response compared to patients genotyped as CYP2D6*1/*1 (42).
Breast cancer recurrence and survival—Because of the extensive biological 
variability across the various clinical settings where tamoxifen is administered (prevention, 
ductal carcinoma in situ, premenopausal and postmenopausal adjuvant setting, and 
metastatic), the current CPIC guidelines focuses only on the role of CYP2D6 genotype in 
the adjuvant treatment of ER+ breast cancer, using the endpoints of recurrence, recurrence-
free survival, disease-free survival, distant relapse-free survival, breast cancer specific 
survival, and overall survival. The body of evidence for each of these clinical endpoints is 
summarized in Table S2. For the clinical endpoints of recurrence and event free-survival, the 
evidence was graded as moderate for the statements that CYP2D6 PMs (AS=0) have a 
higher risk of recurrence or worse event free survival. However, for the comparison of other 
metabolizer groups (IM, NM, and UM) and other clinical endpoints, the evidence was 
considered weak regarding an association between CYP2D6 metabolizer groups and clinical 
outcome (Table S2).
Therapeutic Recommendations
Table 2 summarizes the therapeutic recommendations for tamoxifen prescribing based on 
CYP2D6 phenotype. Based on current evidence (Table S2), CYP2D6 UMs and NMs are 
expected to achieve therapeutic endoxifen concentrations after administration of tamoxifen 
and should receive the recommended standard of care doses of tamoxifen. CYP2D6 PMs 
and IMs (including patients with an activity score of 1.0, see Supplement) are expected to 
have lower endoxifen concentrations compared to NMs and have a higher risk of breast 
cancer recurrence, and worse event-free survival compared to NMs. For CYP2D6 PMs, a 
“strong” therapeutic recommendation was provided to recommend alternative hormonal 
therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor 
along with ovarian function suppression in premenopausal women given that these 
approaches are superior to tamoxifen regardless of CYP2D6 genotype (43, 44) and based on 
knowledge that CYP2D6 PMs patients who switch from tamoxifen to anastrozole do not 
exhibit an increased risk of recurrence (38). Given that escalation of tamoxifen dose from 
20–40 mg/day in CYP2D6 PM significantly increases endoxifen concentrations (but not to 
concentrations achieved in CYP2D6 NMs (45)), the use of an aromatase inhibitor (+/− 
ovarian function suppression) is recommended in this setting. Tamoxifen 40 mg/day can be 
considered for CYP2D6 PM if there are contraindications to AI use. There are no clinical 
data that toremifene, another selective estrogen receptor modulator that also undergoes 
bioactivation (46), should be substituted for tamoxifen based on CYP2D6 genotype.
For CYP2D6 IMs and CYP2D6*10/*10 or CYP2D6*10/decreased function allele, a 
“moderate” recommendation was made to consider use of an alternative hormonal therapy 
(i.e. aromatase inhibitor) for postmenopausal women or aromatase inhibitor plus ovarian 
function suppression in premenopausal women is recommended. In CYP2D6 IMs, if 
aromatase inhibitors are contraindicated, consideration can be given for the use of a higher 
FDA-approved dose of tamoxifen (40 mg/day), which is known to result in significantly 
higher endoxifen concentrations without an increase in toxicity (45). Based on extrapolation 
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from evidence in *10 individuals, a similar recommendation applies to individuals who carry 
other decreased function alleles resulting in an activity score of 1.0 but with an “optional” 
recommendation, given the paucity of data for this group.
In general, prolonged overlap of tamoxifen with strong and moderate CYP2D6 inhibitors 
should be avoided in tamoxifen-treated patients (47), whereas weak inhibitors are also 
contraindicated in CYP2D6 IMs.
Recommendations for Incidental Findings
Not applicable
Other considerations
Pharmacogenetic variation in other cytochrome P450 genes such as CYP2C9 and CYP3A4 
or CYP3A5 is associated with a small effect on plasma concentrations of both 4HT and 
endoxifen with unclear effects on clinical efficacy of tamoxifen. CYP2C19 genotype has 
also been associated with therapy outcome, where IMs and PMs showed an increased 
survival (HR 0.70), and direct effects on endoxifen plasma concentrations were described 
(48–51). Possibly, there is also an increase in tamoxifen drug concentrations, as recently 
suggested (52). While a meta-analysis demonstrated an association between CYP2C19 
genotype and increased survival in tamoxifen treated breast cancer patients (53), an analysis 
of the International Tamoxifen Consortium dataset failed to find this correlation (54), 
leaving the clinical role of CYP2C19 genotyping for tamoxifen therapy unclear at the 
moment.
Implementation of this guideline—The guideline supplement contains resources that 
can be used within electronic health records (EHRs) to assist clinicians in applying genetic 
information to patient care for the purpose of drug therapy optimization (see Resources to 
incorporate pharmacogenetics into an electronic health record with clinical decision support 
sections of Supplement and the CPIC website (6)).
POTENTIAL BENEFITS AND RISKS FOR THE PATIENT
The potential benefit of using CYP2D6 genotype to guide tamoxifen use is that patients with 
genotypes that are associated with a higher risk of breast cancer recurrence, event-free 
survival (e.g., CYP2D6 IMs and PMs) may be identified and alternative doses (e.g. 40 mg) 
and agents administered. Given that the alternative drug treatments (aromatase inhibitors 
either with or without ovarian function suppression) have been demonstrated to be superior 
to tamoxifen (44, 43), and that CYP2D6 PMs switched from tamoxifen to anastrozole do not 
exhibit an increased risk of recurrence (38), it is expected the risks to use CYP2D6 
genotyping to guide hormonal treatment would be low. Further research is necessary, 
however, to determine whether CYP2D6 genotypes associated with therapeutic endoxifen 
concentrations (e.g., NMs and UMs) should be preferentially maintained on tamoxifen. As 
with any laboratory test, a possible risk to patients is an error in genotyping or phenotype 
prediction, along with the presence of a rare genomic variant not tested for, which could 
have long-term adverse health implications for patients.
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CAVEATS: APPROPRIATE USE AND/OR POTENTIAL MISUSE OF GENETIC 
TESTS
Rare CYP2D6 variants may not be included in the genotype test used and patients with rare 
variants may be assigned a "wild-type" (CYP2D6*1) genotype by default. Thus, an assigned 
“wild-type” allele could potentially harbor a no or decreased function variant. Therefore, it 
is important that test reports do include information on which variant alleles were tested. 
Furthermore, it is important that the genetic testing platform includes testing for gene copy 
number.
Like all diagnostic tests, CYP2D6 genotype is one of multiple pieces of information that 
clinicians should consider when making their therapeutic choice for each patient. For 
example, for the treatment of ER+ breast cancer, there are well accepted tumor somatic 
factors that drive endocrine response, including the tumor expression of ER, PR and HER2 
expression, and other multigene assays which are associated with endocrine sensitivity (55). 
Although there are very few data, the implication of reduced CYP2D6 metabolism in 
patients with low risk breast cancer (e.g., early stage breast cancer where the risk of distant 
recurrence is low) may be substantially different than in patients with later stage disease 
with a much higher risk of distant recurrence.
DISCLAIMER
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines reflect expert 
consensus based on clinical evidence and peer-reviewed literature available at the time they 
are written and are intended only to assist clinicians in decision-making, as well as to 
identify questions for further research. New evidence may have emerged since the time a 
guideline was submitted for publication. Guidelines are limited in scope and are not 
applicable to interventions or diseases not specifically identified. Guidelines do not account 
for all individual variation among patients and cannot be considered inclusive of all proper 
methods of care or exclusive of other treatments. It remains the responsibility of the health 
care provider to determine the best course of treatment for the patient. Adherence to any 
guideline is voluntary, with the ultimate determination regarding its application to be solely 
made by the clinician and the patient. CPIC assumes no responsibility for any injury to 
persons or damage to property related to any use of CPIC's guidelines, or for any errors or 
omissions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Assignment of Likely Phenotypes Based on Diplotypes
Phenotypea Genotype Examples of CYP2D6
diplotypesb
Metabolizer Activity Score
CYP2D6 Ultrarapid metabolizer > 2.0 An individual carrying duplications of 
functional alleles
*1/*1xN, *1/*2xN, *2/*2xNc
CYP2D6 Normal metabolizer 1.5 and 2.0 An individual carrying two normal 
function alleles or one normal function 
and one decreased function allele
*1/*1, *1/*2, *1/*9, *1/*41, *2/*2,
CYP2D6 Normal metabolizeror 
Intermediate metabolizer (controversy 
remains)d
1.0 An individual carrying two decreased 
function alleles or one normal function 
and one no function allele.
*1/*4, *1/*5, *41/*41
An activity score (AS) of 1.0 is 
associated with decreased tamoxifen 
metabolism to endoxifen compared to 
those with an AS of 1.5 or 2.
CYP2D6 Intermediate metabolizer 0.5 An individual carrying one decreased 
function and one no function allele
*4/*10,*4/*41, *5/*9




See the CYP2D6 frequency table (1) for race-specific allele and phenotype frequencies.
b
For a complete list of CYP2D6 diplotypes and resulting phenotypes, see the CYP2D6 genotype to phenotype table (1, 6). Note that genotypes 
with an activity score of 1 are classified as NMs in the online CYP2D6 genotype to phenotype table.
c
Where xN represents the number of CYP2D6 gene copies. For individuals with CYP2D6 duplications or multiplications, see supplemental data 
for additional information on how to translate diplotypes into phenotypes.
d
Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories. A group of CYP2D6 experts 
are currently working to standardize the CYP2D6 genotype to phenotype translation system. CPIC will update the CPIC website accordingly 
(CYP2D6 genotype to phenotype table (1, 6)).
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Table 2
Dosing Recommendations for tamoxifen based on CYP2D6 phenotype
Phenotype Implications Therapeutic Recommendationb Classification of
Recommendationa
Metabolizer Status Activity Score
CYP2D6 Ultrarapid metabolizer >2.0 Therapeutic endoxifen concentrations Avoid moderate and strong 
CYP2D6 inhibitors. Initiate 
therapy with recommended 
standard of care dosing 
(tamoxifen 20 mg/day).
Strong
CYP2D6 Normal metabolizer 1.5 to 2.0 Therapeutic endoxifen concentrations Avoid moderate and strong 
CYP2D6 inhibitors. Initiate 
therapy with recommended 
standard of care dosing 
(tamoxifen 20 mg/day).
Strong
CYP2D6 Normal metabolizeror 
Intermediate metabolizer 
(controversy remains)b
1.0 (no *10 
allele 
present)b
Lower endoxifen concentrations 
compared to normal metabolizers; 
higher risk of breast cancer 
recurrence, event-free and 
recurrence-free survival compared to 
normal metabolizers.
Consider hormonal therapy such 
as an aromatase inhibitor for 
postmenopausal women or 
aromatase inhibitor along with 
ovarian function suppression in 
premenopausal women, given 
that these approaches are 
superior to tamoxifen regardless 
of CYP2D6 genotype (43). If 
aromatase inhibitor use is 
contraindicated, consideration 
should be given to use a higher 
but FDA approved tamoxifen 
dose (40 mg/day)(45). Avoid 
CYP2D6 strong to weak 
inhibitors.
Optionalb
CYP2D6 Normal metabolizeror 
Intermediate metabolizer 
(controversy remains)b
1.0 (*10 allele 
present)b
Lower endoxifen concentrations 
compared to normal metabolizers; 
higher risk of breast cancer 
recurrence, event-free and 
recurrence-free survival compared to 
normal metabolizers.
Consider hormonal therapy such 
as an aromatase inhibitor for 
postmenopausal women or 
aromatase inhibitor along with 
ovarian function suppression in 
premenopausal women, given 
that these approaches are 
superior to tamoxifen regardless 
of CYP2D6 genotype (43). If 
aromatase inhibitor use is 
contraindicated, consideration 
should be given to use a higher 
but FDA approved tamoxifen 
dose (40 mg/day)(45). Avoid 
CYP2D6 strong to weak 
inhibitors.
Moderateb
CYP2D6 Intermediate metabolizer 0.5 Lower endoxifen concentrations 
compared to normal metabolizers; 
higher risk of breast cancer 
recurrence, event-free and 
recurrence-free survival compared to 
normal metabolizers.
Consider hormonal therapy such 
as an aromatase inhibitor for 
postmenopausal women or 
aromatase inhibitor along with 
ovarian function suppression in 
premenopausal women, given 
that these approaches are 
superior to tamoxifen regardless 
of CYP2D6 genotype (43). If 
aromatase inhibitor use is 
contraindicated, consideration 
should be given to use a higher 
but FDA approved tamoxifen 
dose (40 mg/day)(45). Avoid 
CYP2D6 strong to weak 
inhibitors.
Moderate
CYP2D6 Poor metabolizer 0 Lower endoxifen concentrations 
compared to normal metabolizers; 
higher risk of breast cancer 
Recommend alternative 
hormonal therapy such as an 
aromatase inhibitor for 
Strong













Goetz et al. Page 15
Phenotype Implications Therapeutic Recommendationb Classification of
Recommendationa
Metabolizer Status Activity Score
recurrence, event-free and 
recurrence-free survival compared to 
normal metabolizers.
postmenopausal women or 
aromatase inhibitor along with 
ovarian function suppression in 
premenopausal women given that 
these approaches are superior to 
tamoxifen regardless of CYP2D6 
genotype (43) and based on 
knowledge that CYP2D6 poor 
metabolizers switched from 
tamoxifen to anastrozole do not 
have an increased risk of 
recurrence (38). Note, higher 
dose tamoxifen (40 mg/day) 
increases but does not normalize 
endoxifen concentrations and can 
be considered if there are 
contraindications to aromatase 
inhibitor therapy (45, 56).
a
Rating scheme described in Supplement.
b
CPIC has generally classified patients with an activity score of 1 as a “normal metabolizer”. However, in the case of tamoxifen, prescribing 
recommendations for those with an AS of 1.0 are allele dependent, based on the presence of the *10 allele. Those patients with an AS of 1.0 on the 
basis a *10 allele are provided a “moderate,” recommendation. In contrast, prescribing recommendations for those with an activity score of 1 based 
on the presence of CYP2D6 alleles other than *10 are graded as “optional” because the recommendations are primarily extrapolated from evidence 
generated from *10 individuals (i.e. limited data for clinical outcomes and pharmacokinetics for this group).
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